Where Will Kestra Medical Stock Be in 1 Year?
Kestra Medical Technologies (NASDAQ:KMTS) is a medical device startup that…
Buy
54
MLTX Quote, Financials, Valuation and Earnings
Last price:
$45.78
Seasonality move
:
43.23%
Day range:
$43.04 - $44.91
52-week range:
$31.42 - $58.26
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
6.99x
Volume:
393.3K
Avg. volume:
552K
1-year change:
16.76%
Market cap:
$2.8B
Revenue:
--
EPS (TTM):
-$2.30
Analysts' Opinion
-
Consensus RatingMoonLake Immunotherapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $78.31, MoonLake Immunotherapeutics has an estimated upside of 74.52% from its current price of $44.87.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $65.00 representing 100% downside risk from its current price of $44.87.
Fair Value
-
According to the consensus of 12 analysts, MoonLake Immunotherapeutics has 74.52% upside to fair value with a price target of $78.31 per share.
MLTX vs. S&P 500
-
Over the past 5 trading days, MoonLake Immunotherapeutics has overperformed the S&P 500 by 0.75% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
MoonLake Immunotherapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
MoonLake Immunotherapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter MoonLake Immunotherapeutics reported revenues of --.
Earnings Growth
-
MoonLake Immunotherapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter MoonLake Immunotherapeutics reported earnings per share of -$0.63.
Enterprise value:
2.4B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-17.46x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$62.1M | -$61M | -$170.8M | -$19.8M | -$47.5M | |
| EBITDA | -$61.9M | -$54.4M | -$161.9M | -$13.6M | -$40M | |
| Diluted EPS | -$1.15 | -$0.73 | -$2.30 | -$0.22 | -$0.63 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $66.5M | $553.6M | $506.3M | |
| Total Assets | -- | -- | $66.8M | $564.1M | $511.3M | |
| Current Liabilities | -- | -- | $7.3M | $8.9M | $24M | |
| Total Liabilities | -- | -- | $7.7M | $11.7M | $98.7M | |
| Total Equity | -- | -- | $59.1M | $552.4M | $412.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$50.7M | -$48.7M | -$139.8M | -$14.9M | -$38.1M | |
| Cash From Investing | -$12.7M | -$73.6M | -$120.5M | -$28.8M | $56.2M | |
| Cash From Financing | $104.7M | $530.7M | $73.5M | $51M | $73.1M | |
| Free Cash Flow | -$50.7M | -$48.9M | -$140.1M | -$15.2M | -$38.2M | |
MLTX
Sector
Market Cap
$2.8B
$32.8M
Price % of 52-Week High
77.02%
46.28%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
16.76%
-35.38%
Beta (5-Year)
--
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$43.77
200-day SMA
Sell
Level
$45.57
Bollinger Bands (100)
Buy
Level
37.45 - 44.31
Chaikin Money Flow
Sell
Level
-3.5M
20-day SMA
Buy
Level
$43.65
Relative Strength Index (RSI14)
Buy
Level
56.93
ADX Line
Buy
Level
20.48
Williams %R
Neutral
Level
-75.1407
50-day SMA
Buy
Level
$40.74
MACD (12, 26)
Buy
Level
1.02
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
24.8M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (6)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
Stock Forecast FAQ
In the current month, MLTX has received 12 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MLTX average analyst price target in the past 3 months is $78.31.
-
Where Will MoonLake Immunotherapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that MoonLake Immunotherapeutics share price will rise to $78.31 per share over the next 12 months.
-
What Do Analysts Say About MoonLake Immunotherapeutics?
Analysts are divided on their view about MoonLake Immunotherapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MoonLake Immunotherapeutics is a Sell and believe this share price will drop from its current level to $65.00.
-
What Is MoonLake Immunotherapeutics's Price Target?
The price target for MoonLake Immunotherapeutics over the next 1-year time period is forecast to be $78.31 according to 12 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MLTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for MoonLake Immunotherapeutics is a Buy. 12 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MLTX?
You can purchase shares of MoonLake Immunotherapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MoonLake Immunotherapeutics shares.
-
What Is The MoonLake Immunotherapeutics Share Price Today?
MoonLake Immunotherapeutics was last trading at $45.78 per share. This represents the most recent stock quote for MoonLake Immunotherapeutics. Yesterday, MoonLake Immunotherapeutics closed at $44.87 per share.
-
How To Buy MoonLake Immunotherapeutics Stock Online?
In order to purchase MoonLake Immunotherapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Howard Marks Buy Grab Stock?
When a legendary value investor who cut his teeth in…
Why Did Warren Buffett Buy Amazon Stock?
When investors think of tech stocks in Warren Buffett’s portfolio,…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 41x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
88
CDTX alert for Jun 24
Cidara Therapeutics [CDTX] is up 3.18% over the past day.
Sell
46
HIMS alert for Jun 24
Hims & Hers Health [HIMS] is up 2.26% over the past day.
Buy
67
WGS alert for Jun 24
GeneDx Holdings [WGS] is up 13.99% over the past day.
